Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Oral administration of PF-06882961 shows evidence of glucose-lowering in healthy human study participants PF-06882961 was selected as a candidate for clinical studies based on its in vitro and in vivo pharmacologic and disposition profile, including potent agonism of the GLP-1R, preclinical disposition attributes (e.g., low metabolic CL int in human hepatocytes), good safety margins versus the hERG channel (IC 50 = 4.3 M, Table S4) and broad panel screening (Table S8), and selectivity versus related class B GPCRs (Table S9)
[Available on 15th April 2002] [Accessed on 19th July 2022] 5
Importantly, when Mounjaro is used in combination with insulin or sulfonylureas, a reduction in the dose of these medications should be considered to reduce the risk of hypoglycaemia
Although, this does require more long term thinking then we tend to do
US$ 20.63
US$ 22.42
US$ 27.37
US$ 19.99
US$ 24.76
US$ 20.85
